PT  - JOURNAL ARTICLE
AU  - Chen, Hsin-Yu
AU  - Gordon, Jeremy W.
AU  - Dwork, Nicholas
AU  - Chung, Brian T.
AU  - Riselli, Andrew
AU  - Sivalokanathan, Sanjay
AU  - Bok, Robert A.
AU  - Slater, James B.
AU  - Vigneron, Daniel B.
AU  - Abraham, M. Roselle
AU  - Larson, Peder E.Z.
TI  - Probing Human Heart TCA Cycle Metabolism and Response to Glucose Load using Hyperpolarized [2-<sup>13</sup>C]Pyruvate MR Spectroscopy
AID  - 10.1101/2023.10.16.23297053
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.16.23297053
4099  - http://medrxiv.org/content/early/2023/10/19/2023.10.16.23297053.short
4100  - http://medrxiv.org/content/early/2023/10/19/2023.10.16.23297053.full
AB  - Introduction The normal heart has remarkable metabolic flexibility that permits rapid switching between mitochondrial glucose oxidation and fatty acid (FA) oxidation to generate ATP. Loss of metabolic flexibility has been implicated in the genesis of contractile dysfunction seen in cardiomyopathy. Metabolic flexibility has been imaged in experimental models, using hyperpolarized (HP) [2-13C]pyruvate MRI, which enables interrogation of metabolites that reflect tricarboxylic acid (TCA) cycle flux in cardiac myocytes. This study aimed to develop methods, demonstrate feasibility for [2-13C]pyruvate MRI in the human heart for the first time, and assess cardiac metabolic flexibility.Methods Good Manufacturing Practice [2-13C]pyruvic acid was polarized in a 5T polarizer for 2.5-3 hours. Following dissolution, QC parameters of HP pyruvate met all safety and sterility criteria for pharmacy release, prior to administration to study subjects. Three healthy subjects each received two HP injections and MR scans, first under fasting conditions, followed by oral glucose load. A 5cm axial slab-selective spectroscopy approach was prescribed over the left ventricle and acquired at 3s intervals on a 3T clinical MRI scanner.Results The study protocol which included HP substrate injection, MR scanning and oral glucose load, was performed safely without adverse events. Key downstream metabolites of [2-13C]pyruvate metabolism in cardiac myocytes include the glycolytic derivative [2-13C]lactate, TCA-associated metabolite [5-13C]glutamate, and [1-13C]acetylcarnitine, catalyzed by carnitine acetyltransferase (CAT). After glucose load, 13C-labeling of lactate, glutamate, and acetylcarnitine from 13C-pyruvate increased by 39.3%, 29.5%, and 114%, respectively in the three subjects, that could result from increases in lactate dehydrogenase (LDH), pyruvate dehydrogenase (PDH), and CAT enzyme activity as well as TCA cycle flux (glucose oxidation).Conclusions HP [2-13C]pyruvate imaging is safe and permits non-invasive assessment of TCA cycle intermediates and the acetyl buffer, acetylcarnitine, which is not possible using HP [1-13C]pyruvate. Cardiac metabolite measurement in the fasting/fed states provides information on cardiac metabolic flexibility and the acetylcarnitine pool.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIND# 145,169Funding StatementThis work was supported by grants from the UCSF Resource Allocation Program Team Science Award, Myokardia Inc. Myoseeds program, NIH (R33HL161816, P41EB013598), and a postdoctoral fellowship from the American Heart Association.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants were recruited with UCSF Institutional Review Board approval (IRB #: 19-27889, PIs: Dr. Maria Roselle Abraham and Dr. Peder Larson) and gave informed consent prior to participation in this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets analyzed during the current study are available from the corresponding author on reasonable request.TCA cycletricarboxylic acid cycleFAfatty acidALCARacetylcarnitineCATcarnitine acetyltransferase